Outpatient cardiac rehabilitation dose after acute coronary syndrome in a nationwide cohort

Kanaoka, Koshiro; Iwanaga, Yoshitaka; Nakai, Michikazu; Nishioka, Yuichi; Myojin, Tomoya; Kubo, Shinichiro; Okada, Katsuki; Soeda, Tsunenari; Noda, Tatsuya; Sakata, Yasushi; Miyamoto, Yoshihiro; Saito, Yoshihiko; Imamura, Tomoaki

doi:10.1136/heartjnl-2021-320434

Cited by 7 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Japan has a universal multi-payer health insurance coverage system, and the original NDB contains data on almost all healthcare services provided by healthcare institutions in Japan. 10 We used a patient-matching technique, and the database was available for longitudinal patient follow-up. 11 Based on this method, we could follow >90% of the patients for 3 years.…”

Section: Methodsmentioning

confidence: 99%

Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks

Kanaoka,

Nishida,

Iwanaga

et al. 2023

European Heart Journal

Self Cite

View full text Add to dashboard Cite

Background and Aims Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score. Methods This retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thromboembolism and major bleeding after a landmark period of 6 months. After inverse probability of treatment weighting analysis, the association between OAC continuation and outcomes was determined according to the CHADS2 score. Results Among 231 374 patients included, 69.7%, 21.6%, and 8.7% had CHADS2 scores of ≤1, 2, and ≥3, respectively. Of these, 71% continued OAC therapy at 6 months. The OAC continuation rate was higher in the high CHADS2 score group than that in the low CHADS2 score group. Among all patients, 2451 patients (0.55 per 100 person-years) had thromboembolism and 2367 (0.53 per 100 person-years) had major bleeding. In the CHADS2 score ≤1 group, the hazard ratio of the continued OAC group was 0.86 [95% confidence interval (CI): 0.74–1.01, P = .06] for thromboembolism and was 1.51 (95% CI: 1.27–1.80, P < .001) for major bleeding. In the CHADS2 score ≥3 group, the hazard ratio of the continued OAC group was 0.61 (95% CI: 0.46–0.82, P = .001) for thromboembolism and was 1.05 (95% CI: 0.71–1.56, P = 0.81) for major bleeding. Conclusions This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient’s CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.

show abstract

Section: Methodsmentioning

confidence: 99%